Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioRelix has signed a research collaboration agreement with a subsidiary of Merck & Co to identify new antibacterial drug candidates.
Subscribe to our email newsletter
As per the agreement, BioRelix is expected to use its proprietary riboswitch technology platform to identify compounds with activity against a number of bacterial targets.
The parties will jointly undertake preclinical programs, and Merck will subsequently be responsible for clinical evaluation of any candidates chosen for further development.
Under the contract, BioRelix is expected to get an upfront fee and research funding from Merck, and is also eligible to receive payments upon achievement of specified milestones associated with advancement of drug candidates and royalties on the sales of any products derived from the collaboration.
Merck Research Laboratories senior vice president and Infectious Diseases global franchise head Roger Pomerantz said that collaborations with companies like BioRelix are essential as we seek to apply the latest innovative drug discovery technologies towards the discovery of new much needed antibacterial medications.